Health
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
PALO ALTO, Calif. & ROCHESTER, Minn., February 02, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for MRD detection in patients with resected stage III colon cancer after surgery and before adjuvant chemotherapy. Results of the study, published in the Journal of Clinical Oncolog
About this update from Guardant Health, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1806,"height":619,"url":"https://media.zenfs.com/en/business-wire.com/04b72dc68adb9f2002b27876a2d85eb2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vLnU6HtwVICyr0LiRMouEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/04b72dc68adb9f2002b27876a2d85eb2","width":960,"height":329},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/PTemAgOdTt0CDKUft5hKPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MjI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/04b72dc68adb9f2002b27876a2d85eb2","width":1200,"height":411}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Data published in Journal of Clinical Oncology supports routine use of circulating tumor DNA (ctDNA) testing in management of stage III colon cancer patients","length":157,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":157,"olType":false},{"type":"text","content":"PALO ALTO, Calif. & ROCHESTER, Minn., February 02, 2026--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for MRD detection in patients with resected stage III colon cancer after surgery and before adjuvant chemotherapy. Results of the study, published in the Journal of Clinical Oncology, show that detecting ctDNA with the Guardant Reveal® blood test better predicts recurrence and overall survival than standard staging.","length":657,"tagName":"p"},{"type":"text","content":"Researchers found that about 20 percent of patients in the phase III trial, which was presented at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, involving more than 2,000 patients still had detectable ctDNA in their blood after surgery. Guardant Reveal identified patients at a four-to-six-fold higher rate of disease recurrence or reduced survival. Even patients with smaller tumors or fewer affected lymph nodes found as part of traditional staging had an over 6-fold higher rate of events if ctDNA was detected. The findings support the integration of tissue-f...